



ASX ANNOUNCEMENT

30 September 2021

Share purchase plan offer closing date extended

30 September 2021 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) refers to the Share Purchase Plan (**SPP**) announced on 7 September 2021 and advises that the closing date for applications has been extended by ten days, to **5.00pm (Melbourne time) on Friday, 15 October 2021**.

The Company has been made aware that many of its shareholders have experienced difficulties in either receiving materials due to postal delays, or accessing the SPP online platform.

The extension has been granted to ensure that all eligible shareholders have an opportunity to participate in the SPP.

Shareholders who have already applied for shares under the SPP do not need to take any further action unless they wish to apply for additional shares, up to a maximum application amount of \$30,000, as referred to in the SPP offer documents released on 13 September 2021.

All other terms of the SPP remain the same.

An updated SPP timetable is below:

Event	Date
SPP Offer closes	5:00pm (Melbourne time) Friday, 15 October 2021
Completion announcement date (and notice of scale backs, if any)	Thursday, 21 October 2021
Allotment Date	Friday, 22 October 2021
Dispatch Holding Statements	Monday, 25 October 2021

The above timetable is indicative only and subject to change at the discretion of the Company.

The Company welcomes the support it has received from shareholders for the SPP to date and looks forward to completing this important capital raise.

Authorised for release by the Board of Directors of Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 3 9095 7088
clive.fanning@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouplimited.com | www.satipharm.com